Geron is a clinical-stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Telomerase is an enzyme that enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. Imetelstat is a specific inhibitor of telomerase. Geron focuses to develop imetelstat to treat one or more hematologic myeloid malignancies, such as myelofibrosis (MF), myelodysplastic syndromes (MDS), or acute myelogenous leukemia (AML).
Address
149 Commonwealth Drive
MENLO PARK, CA 94025
United States
MENLO PARK, CA 94025
United States
Key stats and ratios
| Q2 (Jun '13) | 2012 | |
| Net profit margin | -7988.39% | -2542.67% |
| Operating margin | -8004.46% | -2648.87% |
| EBITD margin | - | -2518.49% |
| Return on average assets | -45.93% | -53.02% |
| Return on average equity | -49.68% | -59.31% |
| Employees | 105 |
No comments:
Post a Comment